Literature DB >> 25097844

The Effect of Chlorella vulgaris Supplementation on Liver En-zymes, Serum Glucose and Lipid Profile in Patients with Non-Alcoholic Fatty Liver Disease.

Mehrangiz Ebrahimi-Mameghani1, Soodabeh Aliashrafi2, Yousef Javadzadeh3, Mohammad AsghariJafarabadi4.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is becoming a public health problem worldwide and using microalgae is a new approach on its treatment. The aim of this study was to investigate the effect of Chlorella vulgaris supplementation on liver enzymes, serum glucose and lipid profile in patients with NAFLD.
METHODS: This double-blind randomized placebo-controlled clinical trial was conducted on 60 NAFLD patients from specialized clinics of Tabriz University of Medical Sciences from December 2011 to July 2012. The subjects were randomly allocated into 2 groups: 1) "intervention" (n=30) received 400 mg/day vitamin E plus four 300 mg tablets of Chlorella vulgaris and, 2) "placebo" (n=30) received 400 mg/day vitamin E and four placebo tablets per day for 8 weeks. Weight, liver enzymes and metabolic factors were assessed in fasting serum and dietary data was collected at baseline and end of the study.
RESULTS: Weight, liver enzymes, fasting blood sugar (FBS) and lipid profile decreased significantly in both groups (P<0.05). The differences in weight, ALP and FBS between the two groups were statistically significant (P=0.01, P=0.04 and P=0.02, respectively).
CONCLUSION: C. vulgaris seems to improve FBS and lipid profile and therefore could be considered as an effective complementary treatment in NAFLD.

Entities:  

Keywords:  Chlorella vulgaris; Functional food; Liver enzymes; Microalgae; Non-alcoholic fatty liver disease

Year:  2014        PMID: 25097844      PMCID: PMC4122038          DOI: 10.5681/hpp.2014.014

Source DB:  PubMed          Journal:  Health Promot Perspect        ISSN: 2228-6497


  30 in total

1.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

Authors:  T Ueno; H Sugawara; K Sujaku; O Hashimoto; R Tsuji; S Tamaki; T Torimura; S Inuzuka; M Sata; K Tanikawa
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  Potential hypoglycemic effects of Chlorella in streptozotocin-induced diabetic mice.

Authors:  Cherng Jong-Yuh; Shih Mei-Fen
Journal:  Life Sci       Date:  2005-04-07       Impact factor: 5.037

Review 3.  Obesity and liver disease: the epidemic of the twenty-first century.

Authors:  Kathleen E Corey; Lee M Kaplan
Journal:  Clin Liver Dis       Date:  2014-02       Impact factor: 6.126

4.  Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.

Authors:  Yunes Panahi; Mohammad Ebrahim Ghamarchehreh; Fatemeh Beiraghdar; Rnmarjan Zare; Hamid Reza Jalalian; Amirhossein Sahebkar
Journal:  Hepatogastroenterology       Date:  2012-10

5.  Improving glycogenesis in Streptozocin (STZ) diabetic mice after administration of green algae Chlorella.

Authors:  Jong-Yuh Cherng; Mei-Fen Shih
Journal:  Life Sci       Date:  2005-11-14       Impact factor: 5.037

6.  Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis.

Authors:  Chalamalasetty Sreenivasa Baba; George Alexander; Bikkasani Kalyani; Rakesh Pandey; Sujata Rastogi; Amaresh Pandey; Gourdas Choudhuri
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

Review 7.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.

Authors:  Chin Hee Kim; Zobair M Younossi
Journal:  Cleve Clin J Med       Date:  2008-10       Impact factor: 2.321

8.  Anti-inflammatory and immunomodulatory activities of polysaccharide from Chlorella stigmatophora and Phaeodactylum tricornutum.

Authors:  S Guzmán; A Gato; M Lamela; M Freire-Garabal; J M Calleja
Journal:  Phytother Res       Date:  2003-06       Impact factor: 5.878

9.  Hypoglycemic effect of Chlorella vulgaris intake in type 2 diabetic Goto-Kakizaki and normal Wistar rats.

Authors:  Hyejin Jeong; Hye Jin Kwon; Mi Kyung Kim
Journal:  Nutr Res Pract       Date:  2009-03-31       Impact factor: 1.926

10.  Focus on therapeutic strategies of nonalcoholic Fatty liver disease.

Authors:  Marilena Durazzo; Paola Belci; Alessandro Collo; Enrica Grisoglio; Simona Bo
Journal:  Int J Hepatol       Date:  2012-11-08
View more
  7 in total

1.  Therapeutic effects of Chlorella vulgaris on carbon tetrachloride induced liver fibrosis by targeting Hippo signaling pathway and AMPK/FOXO1 axis.

Authors:  Roohollah Mohseni; Seyed Moayed Alavian; Zahra Arab Sadeghabadi; Mohammad Heiat
Journal:  Mol Biol Rep       Date:  2020-12-09       Impact factor: 2.316

2.  Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial.

Authors:  Mehrangiz Ebrahimi-Mameghani; Haleh Jamali; Reza Mahdavi; Farzad Kakaei; Rana Abedi; Bita Kabir-Mamdooh
Journal:  Croat Med J       Date:  2016-08-31       Impact factor: 1.351

3.  Quantifying the Effect of Supplementation with Algae and Its Extracts on Glycolipid Metabolism: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Kun-Xiang Ding; Tian-Lin Gao; Rui Xu; Jing Cai; Hua-Qi Zhang; Yong-Ye Sun; Feng Zhong; Ai-Guo Ma
Journal:  Nutrients       Date:  2020-06-08       Impact factor: 5.717

Review 4.  Potential of Chlorella as a Dietary Supplement to Promote Human Health.

Authors:  Tomohiro Bito; Eri Okumura; Masaki Fujishima; Fumio Watanabe
Journal:  Nutrients       Date:  2020-08-20       Impact factor: 5.717

Review 5.  Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease.

Authors:  Maitane González-Arceo; Saioa Gómez-Zorita; Leixuri Aguirre; María P Portillo
Journal:  Nutrients       Date:  2021-06-11       Impact factor: 5.717

6.  Chlorella vulgaris in combination with high intensity interval training in overweight and obese women: a randomized double-blind clinical trial.

Authors:  Mahzad Sanayei; Azimeh Izadi; Fatemeh Hajizadeh-Sharafabad; Ramin Amirsasan; Mojtaba Kaviani; Ali Barzegar
Journal:  J Diabetes Metab Disord       Date:  2021-05-31

Review 7.  The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.

Authors:  Reem Abou Assi; Ibrahim M Abdulbaqi; Chan Siok Yee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.